Benefit and risk of methotrexate treatment in rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 22, Issue 5 SUPPL. 35, 2004, Pages

  Rau, Rolf ^a   Herborn, Gertraud ^a  

^a Rheumaklinik   (Germany)

Author keywords

MTX efficacy; MTX toxicity; MTX treatment; Review article; Rheumatoid arthritis

Indexed keywords

AMINOTRANSFERASE; AURANOFIN; AZATHIOPRINE; CHLOROQUINE; CYCLOSPORIN A; ETANERCEPT; ETODOLAC; FOLIC ACID; GOLD; HYDROXYCHLOROQUINE; IBUPROFEN; INFLIXIMAB; KETOPROFEN; LEFLUNOMIDE; MELOXICAM; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PIROXICAM; PLACEBO; PREDNISONE; PROBENECID; SALAZOSULFAPYRIDINE; SALICYLIC ACID DERIVATIVE; DISEASE MODIFYING ANTIRHEUMATIC DRUG;

ALLERGIC PNEUMONITIS; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; BONE MARROW TOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONGENITAL MALFORMATION; COUGHING; CYANOSIS; CYTOPENIA; DISEASE EXACERBATION; DIZZINESS; DOSE KIDNEY FUNCTION RELATION; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED CANCER; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG OXIDATION; DRUG POTENTIATION; DRUG TOLERABILITY; DYSPNEA; EPSTEIN BARR VIRUS; FATIGUE; FIBROSING ALVEOLITIS; FOLIC ACID DEFICIENCY; GASTROINTESTINAL SYMPTOM; GRANULOMATOUS VASCULITIS; GYNECOMASTIA; HEADACHE; HEART DEATH; HEART DISEASE; HEMATOLOGIC DISEASE; HEPATITIS; HEPATITIS B; HERPES ZOSTER; HODGKIN DISEASE; HUMAN; HYPOXEMIA; IMPOTENCE; KIDNEY DYSFUNCTION; LEUKEMIA; LEUKOPENIA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FIBROSIS; LIVER NECROSIS; LIVER TOXICITY; LOW DRUG DOSE; LUNG COMPLICATION; LUNG GRANULOMA; LUNG INFILTRATE; LUNG NODULE; MAINTENANCE DRUG DOSE; MALAISE; MAXIMUM TOLERATED DOSE; MEDICAL LITERATURE; MOOD DISORDER; MYALGIA; MYCOSIS; NAUSEA; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; OLIGOSPERMIA; OPPORTUNISTIC INFECTION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PANCYTOPENIA; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SKIN MANIFESTATION; SKIN NODULE; SMALL VESSEL VASCULITIS; STOMATITIS; THROMBOCYTOPENIA; TUBERCULOSIS; URTICARIA; VERTIGO; VIRUS INFECTION; VOMITING; WOUND HEALING IMPAIRMENT; WOUND INFECTION; ARTICLE; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG SAFETY; FEVER; JOINT DESTRUCTION; LUNG DISEASE; PREVALENCE; RENAL CLEARANCE; SIDE EFFECT; TREATMENT OUTCOME; URINARY TRACT INFECTION; VITAMIN SUPPLEMENTATION; WOUND HEALING;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; METHOTREXATE; RISK ASSESSMENT;

EID: 5044239441     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (217)

1. SMOLEN JS, BREEDVELD FC, BURMESTER GR et al.: Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis. Ann Rheum Dis 2000; 59: 504-5.
2. PINCUS T, YAZICI Y, SOKKA T, ALETAHA D, SMOLEN JS: Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003; 21 (Suppl. 31): S179-85.
3. HERMAN RA, VAN PEDERSEN P, HOFFMAN J, FURST DE: Pharmacokinetics of low dose methotrexate in rheumatoid arthritis patients. J Pharm Sci 1989; 78: 165-71.
4. AUVINET B, JARRIER I, LE-LEVIER F et al.: Comparative bioavailability of methotrexate given orally or intramuscularly in rheumatoid arthritis. Presse Med 1992; 21: 822.
5. OGUEY D, KÖLLIKER F, GERBER NJ, REICHEN J: Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1992; 35: 611-4.
6. KORBER H, IVEN H, GROSS WL: Bioavailability and pharmacokinetics of methotrexate 6and its metabolite 7-hydroxy-MTX after low-dose MTX (25 mg) in patients with chronic rheumatoid diseases. Arthritis Rheum 1992;35: S142 (abstract).
7. HOEKSTRA M, HAAGSMA C, NEEF C et al.: Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 2004; 31: 645-48.
8. ANAYA JM, FABRE D, BRESSOLLE F et al.: Unchanged methotrexate pharmacokinetics upon initial therapy compared with prolonged therapy in rheumatoid arthritis. Arthritis Rheum 1992; 35: 142.
9. HAMILTON RA, KREMER JM: Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997; 36: 86-90.
10. Rheumatoid Arthritis Clinical Trial Archive Group: The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. J Rheumatol 1995; 22: 218-23.
11. BRESOLLE F, BOLOGNA C, KINOWSKI JM et al.: Total and free methotrexate pharmacokinetics in elderly patients with rheumatoid arthritis. A comparison with young patients. J Rheumatol 1997; 24: 1903-9.
12. FURST DE: Pharmacocinetics of very low dose methotrexate. In RAU R (Ed.): Low Dose Methotrexate Therapy in Rheumatoid Diseases. Karger, 1986, Basel.
13. KREMER JM, GALIVAN J, STRELKFUSS A, KAMEN B: Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 1986; 29: 832-5.
14. CRONSTEIN BN: Molecular therapeutics - Methotrexate and its mechanism of action. Arthritis Rheum 1996; 39: 1951-60.
15. GERARDS AH, DE LATHOUDER S, DE GROOT ER et al.: Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology 2003; 42: 1189-96.
16. SEGAL R, CASPI D, TISHLER M et al.: Short term effects of low dose methotrexate on the acute phase reaction in patients with rheumatoid arthritis. J Rheumatol 1989; 16: 914-917.
17. EVANS WE, CHRISTENSEN ML: Drug interactions with methotrexate. J Rheumatol 1985; 12 (Suppl.): 15-20.
18. HÜBNER G, SANDER O, DEGNER FL, TURCK D, RAU R: Lack of pharmacokinetic interaction of meloxicam with methotrexate in patients with rheumatoid arthritis. J Rheumatol 1997; 24: 845-51.
19. ROONEY T, FURST DE: Methotrexate. In McCARTY DJ (Ed.): Arthritis and Allied Conditions, 12th ed. Philadelphia, Lea & Febiger 1992; 621-36.
20. KREMER JM, HAMILTON RA: The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. J Rheumatol 1995; 22: 2072-7.
21. LAFFORGUE P, MONJANEL-MOUTERDE S, DURAND A et al.: Is there an interaction between low doses of corticosteroids and methotrexate in patients with rheumatoid arthritis ? J Rheumatol 1993; 20: 263-7.
22. AHERN GW, PIALL E, MARKS V: Prolongation and enhancement of serum methotrexate concentrations by probenecid. Br Med J 1978; 1: 1097-9.
23. SEIDEMAN P, ALBERTIONI F, BECK O et al.: Chloroquine reduces the bioavailability of methotrexate in patients with rheumatoid arthritis. A possible mechanism of reduced hepatotoxicity. Arthritis Rheum 1994; 37:830-3.
24. CARMICHAEL SJ, BEAL J, O'DAY R, TETT SE: Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate. J Rheumatol 2002; 29: 2077-83.
25. FOX RI, MORGAN SL, SMITH HAT et al.: Combined oral cyclosporin and methotrexate therapy in patients with rheumatoid arthritis elevates methotrexate levels and reduces 7-hydroxymethotrexate levels when compared with methotrexate alone. Rheumatology 2003; 42: 989-94.
26. GUBNER R, AUGUST S, GINSBERG V: Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1951; 221: 176-82.
27. GROSS D, ENDERLIN M, FEHR K: Immunosuppressive treatment of RA with cytotoxic agents (in German). Schweiz Med Wschr 1967; 97: 1301.
28. HOFFMEISTER RT: Methotrexate in rheumatoid arthritis. Arthritis Rheum 1972; 15: 114 (abstract).
29. WILLKENS RE et al.: Low-dose pulse methotrexate in rheumatoid arthritis. J Rheumatol 1980; 7: 501-5.
30. WILKE WS, CALABRESE LH, SCHERBEL AL: Methotrexate in the treatment of rheumatoid arthritis. Pilot study. Cleve Clin Q 1980; 47: 305-9.
31. HOFFMEISTER RT: Methotrexate therapy in rheumatoid arthritis: 15 years experience. Am J Med 1983; 75: 69-73.
32. KARGER T, RAU R: Treatment of rheumatoid arthritis with methotrexate (in German). Z Rheumatol 1982; 41: 164.
33. ANDERSEN PA, WEST SG, O'DELL JR et al.: Weekly pulse methotrexate in rheumatoid arthritis. Ann Intern Med 1985; 103: 489-96.
34. THOMPSON RN, WATTS C, EDELMAN J, RUSSELL AS: A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Rheumatol 1984; 11: 760-2.
35. WEINBLATT ME, COBLYN JS, FOX DA et al.: Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312: 818-22.
36. WILLIAMS HJ, WILLKENS RF, SAMUELSON CO et al.: Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis - A controlled clinical trial. Arthritis Rheum 1985; 28: 721-9.
37. FURST DE, KOEHNKE R, BURMEISTER LF et al.: Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol 1989; 16: 313-20.
38. RAU R, HERBORN G: Intravenous treatment of highly active rheumatoid arthritis with methotrexate. In RAU R (Ed.): Low Dose Methotrexate Therapy in Rheumatic Diseases. Basel, Karger, 1986.
39. MICHAELS RM, NASHEL DJ, LEONARD A, SLIWINSKI J, DERBES SJ: Weekly intravenous methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 1982; 25: 339-41.
40. KREMER JM, LEE JK: The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 1986; 29: 822-31.
41. KREMER JM, PHELPS CT: Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 1992; 35: 138-45.
42. WEINBLATT ME, TRENTHAM DE, FRASER PA: Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum 1988; 31: 167-75.
43. WEINBLATT ME, WEISSMAN BN, HOLDSWORTH DE et al.: Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Arthritis Rheum 1992; 35: 129-37.
44. WEINBLATT ME, MAIER AL, FRASER PA, COBLYN JS: Long-term prospective study of methotrexate in rheumatoid arthritis: Conclusion after 132 month of therapy. J Rheumatol 1998; 25: 238-42.
45. WEINBLATT ME, KAPLAN H, GERMAIN BF et al.: Methotrexate in rheumatoid arthritis. A five-year prospective multi-center study. Arthritis Rheum 1994; 37: 1492-8.
46. SANY J, ANAYA JM, LUSSIEZ V et al.: Treatment of rheumatoid arthritis with methotrexate: a prospective open long-term study of 191 cases. J Rheumatol 1991; 18: 1323-7.
47. HANRAHAN PS, SCRIVENS GA, RUSSELL AS: Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: Toxicity, efficacy and radiological progression. Br J Rheumatol 1989; 28: 147-53.
48. ALARCON GS, TRACY IC, BLACKBURN WD Jr: Methotrexate in rheumatoid arthritis: toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum 1989; 32: 671-6.
49. MIELANTS H, VEYS EM, VAN DER STRAETEN C, ACKERMAN C, GOEMAERE S: The efficacy and toxicity of a constant low dose of methotrexate as a treatment for intractable rheumatoid arthritis: An open prospective study. J Rheumatol 1991; 18: 978-83.
50. RAU R, KARGER T: Clinical experience with methotrexate in the treatment of rheumatoid arthritis (in German). Internistische Welt 1987; 12: 335-48.
51. RAU R, SCHLEUSSER B, HERBORN G, KARGER T: Long-term treatment of destructive rheumatoid arthritis with methotrexate. J Rheumatol 1997; 24: 1881-9.
52. BOLOGNA C, VIU P, PICOT MC et al.: Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study. Br J Rheumatol 1997; 36: 535-40.
53. PINALS RS, MASI AT, LARSEN RA and Subcommittee for Criteria of Remission in Rheumatoid Arthritis of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24: 1308-15.
54. WOLFE F, CATHEY MA: The effect of age on methotrexate efficacy and toxicity. J Rheumatol 1991; 18: 973-7.
55. POOLE P, YEOMAN S, CAUGHEY D: Methotrexate in older patients with rheumatoid arthritis. Br J Rheumatol 1992; 31: 860.
56. BUCHBINDER R, HALL S, SAMBROOK PN et al.: Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice. J Rheumatol 1993; 20: 639-44.
57. HAWLEY DJ, WOLFE F: Are the results of controlled clinical trials and observational studies of second line therapy in rheumatoid arthritis valid and generalisable as measures of outcome: analysis of 122 studies. J Rheumatol 1991; 18: 1008-14.
58. PINCUS T, CALLAHAN LF: Methotrexate is significantly more likely to be continued over two years than gold salts, penicillamine or hydroxychloroquine in rheumatoid arthritis. Arthritis Rheum 1989; 32: 128.
59. WLUKA A, BUCHBINDER R, MYLVAGANAM A et al.: Long-term methotrexate use in rheumatoid arthritis: 12-year follow-up of 460 patients treated in community practice. J Rheumatol 2000; 27: 1864-71.
60. McKENDRY RJR, DALE P: Adverse effects of low-dose methotrexate therapy in rheumatoid arthritis. J Rheumatol 1993; 20: 1850-6.
61. FURST DE: Proposition: Methotrexate should not be the first second-line agent to be used in rheumatoid arthritis if NSAIDs fail. Arthritis Rheum 1990; 20: 69-75.
62. ORTENDAHL M, HOLMES T, SCHETTLER JD, FRIES JF: The methotrexate therapeutic response in rheumatoid arthritis. J Rheumatol 2002; 29: 2084-91.
63. WOLFE F, CATHEY MA: The effect of age on methotrexate efficacy and toxicity. J Rheumatol 1991; 18: 973-7.
64. POOLE P, YEOMAN S, CAUGHEY D: Methotrexate in older patients with rheumatoid arthritis. Br J Rheumatol 1992; 31: 860.
65. SCOTT DL, PUGNER K, KAARELA K et al.: The links between joint damage and disability in rheumatoid arthritis. Rheumatology 2000; 39: 122-32.
66. SANY J, KALISKI S, COURET M et al.: Radiologic progression during intramuscular methotrexate treatment of rheumatoid arthritis. J Rheumatol 1990; 17: 1636-41.
67. DROSOS AA, KARANTANAS AH, PSYCHOS D et al.: Can treatment with methotrexate influence the radiological progression of rheumatoid arthritis ? Clin Rheumatol 1990; 9: 342-5.
68. REYKDAL S, STEINSSON K, SIGURJONSSON K, BREKKAN A: Methotrexate treatment of rheumatoid arthritis: effects on radiological progression. Scand J Rheumatol 1989; 18: 221-6.
69. RAU R, HERBORN G, KARGER T, WERDIER D: Retardation of radiologic progression in rheumatoid arthritis with methotrexate therapy. Arthritis Rheum 1991; 10: 1236-44.
70. NORDSTROM DM, WEST SG, ANDERSEN PA, SHARP JT: Pulse methotrexate therapy in rheumatoid arthritis. A controlled prospective roentgenographic study. Ann Intern Med 1987; 107: 797-801.
71. RAU R, HERBORN G, MENNINGER H, SANGHA O: Progression in early erosive rheumatoid arthritis: 12-month results from a randomised controlled trial comparing methotrexate and gold sodium thiomalate. Br J Rheumatol 1998; 37: 1220-6.
72. RAU R, HERBORN G, MENNINGER H, SANGHA O: Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients. Rheumatology 2002; 41: 196-204.
73. JEURISSEN MEC, BOERBOOMS AMTH, VAN DE PUTTE LBA et al.: Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight-week randomised, double-blind trial. Arthritis Rheum 1991; 34: 951-60.
74. ALARCON GS, LOPEZ-MENDEZ A, WALTER J et al.: Radiographic evidence of disease progression in methotrexate-treated and non-methotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients. A meta-analysis. J Rheumatol 1992; 19: 1868-73.
75. WEINBLATT ME, POLISSON R, BLOTNER SD et al.: The effects of drug therapy on radiographic progression of rheumatoid arthritis. Arthritis Rheum 1993; 5: 613-9.
76. WEINBLATT ME, KAPLAN H, GERMAIN BF: Low dose methotrexate compared with auranofin in adult rheumatoid arthritis. Arthritis Rheum 1990; 33: 330-8.
77. WILLIAMS HJ, WARD JR, READING JC et al.: Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. Arthritis Rheum 1992; 3:259-69.
78. MORRASUT T, GOLDSTEIN R, CYR M et al.: Gold sodium thiomalat compared to low-dose methotrexate in the treatment of rheumatoid arthritis - a randomised double-blind 26-week trial. J Rheumatol 1989; 16: 302-6.
79. SUAREZ-ALMAZOR ME, FITZGERALD A, GRACE M, RUSSELL AS: A randomised controlled trial of parenteral methotrexate compared with sodium aurothiomalate. J Rheumatol 1988; 15: 753-6.
80. RAU R, HERBORN G, KARGER T et al.: A double blind randomised parallel trial of intramuscular methotrexate and gold sodium thiomalate in early erosive rheumatoid arthritis. J Rheumatol 1991; 18: 328-33.
81. RAU R, HERBORN G, MENNINGER H, BLECHSCHMIDT J: Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12-month data of a double-blind parallel study of 174 patients. Br J Rheumatol 1997; 36: 345-52.
82. MENNINGER H, HERBORN G, BLECH-SCHMIDT J, RAU R: A 36-month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis. Br J Rheumatol 1998; 1060-8.
83. HAMILTON J, McINNES IB, THOMON ES et al.: Comparative study of intramuscular gold and methotrexate in a rheumatoid arthritis population from a socially deprived area. Ann Rheum Dis 2001; 60: 566-72.
84. HAMDY H, McKENDRY RJR, MIERINS E, LIVER JA: Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. Arthritis Rheum 1987; 30: 361-8.
85. FELSON DT, ANDERSON JJ, MEENAN RF: The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Arthritis Rheum 1990; 33: 1449-60.
86. STRAND V, COHEN S, SCHIFF M et al.: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159: 2542-50.
87. COHEN S, CANNON GW, SCHIFF M et al.: Two year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum 2001; 44: 1984-92.
88. EMERY P, BREEDVELD FC, LEMMEL EM et al.: A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 2000; 39: 655-65.
89. BATHON JM, MARTIN RW, FLEISCHMANN RM et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93.
90. GENOVESE MC, BATHON JM, MARTIN RW et al.: Etanercept versus methotrexate in patients with early rheumatoid arthritis. Two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 45: 1443-50.
91. HOCHBERG MC, TRACY JJK, HAWKINS-HOLT M, FLORES RH: Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003; 62 (Suppl. 2): ii13-16.
92. RAU R: Have traditional DMARDS had their day? Clin Rheumatol (in press).
93. O'DELL JR, HAIRE CE, ERIKSON N et al.: Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334: 1287-91.
94. MÖTTÖNEN T, HANNONEN P, LEIRISALOREPO M et al.: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomized trial. FIN-RACo trial group. Lancet 1999; 353:1568-73.
95. BOERS M, RAMSDEN M: Long-acting drug combinations in rheumatoid arthritis: a formal overview. J Rheumatol 1991; 18: 316-24.
96. VERHOEVEN AC, BOERS M, TUGWELL P: Combination therapy in rheumatoid arthritis: updated systematic review. Br J Rheumatol 1998; 37: 612-19.
97. WILLKENS RF, UROWITZ MB, STABLEIN DM et al.: Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: A controlled clinical trial. Arthritis Rheum 1992; 35:849-56.
98. WILLKENS RF, STABLEIN D: Combination treatment of rheumatoid arthritis using azathioprine and methotrexate: a 48-week controlled clinical trial. J Rheumatol 1996; 44:64-8.
99. FERRAZ MB, PINHEIRO GR, HELFENSTEIN M et al.: Combination therapy with methotrexate and chloroquine in rheumatoid arthritis. A multicenter randomised placebo-controlled trial. Scand J Rheumatol 1994; 23:231-6.
100. DOUGADOS M, COMBE B, CANTAGREL A et al.: Combination therapy in early rheumatoid arthritis: A randomized, controlled, double-blind 52-week clinical trial of sulfasalazine and methotrexate versus the single components. Ann Rheum Dis 1998; 58:220-5.
101. HAAGSMA CJ, VAN RIEL PL, DE JONG AJ, VAN DE PUTTE LB: Combination of sulfasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomised, controlled, double-blind, 52-week clinical trial. Br J Rheumatol 1997; 36: 1082-8.
102. O'DELL JR, HAIRE C, ERIKSON N et al.: Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate. J Rheumatol 1996; 44: 72-4.
103. O'DELL JR, LEFF R, PAULSEN G: Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1164-70.
104. TUGWELL P, PINCUS T, YOCUM D: Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995; 333: 137-41.
105. STEIN CM, PINCUS T, YOCUM D et al.: Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks: an open-label extension study. Arthritis Rheum 1997; 40: 1843-51.
106. GERARDS AH, LANDEWE RB, PRINS AP et al.: Cyclosporin A monotherapy versus cyclosporine A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double-blind randomised placebo controlled trial. Ann Rheum Dis 2003; 62:291-6.
107. MARCHESONI A, BATTAFARANO N, ARREGHINI M et al.: Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatology 2003; 42: 1545-9.
108. KREMER JM, GENOVESE MC, CANNON GW, CALDWELL JR, CUSH JJ: Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137: 726-33.
109. VELAGAPUDI RB, NOERTERSHEUSER PA, AWNI WM et al.: Effect of methotrexate (MTX) coadministration on the pharmacokinetics (PK) of adalimumab (HUMIRA™, Abbott) following a single intravenous (iv) injection. Arthritis Rheum 2003; 48: S 140 (abstract).
110. ALLEN LS, GROFF G: Treatment of Felty's syndrome with low-dose oral methotrexate. Arthritis Rheum 1986; 29: 902-5.
111. ISASY C, LOPEZ-MARTIN JA, TRUJILLO MA, ANDREU JL, PALACIO S, MULERO J: Felty's syndrome: Response to low dose oral methotrexate. J Rheumatol 1989; 16: 983-5.
112. FIECHTNER JJ, MILLER DR, STARLEBAUM GA: Methotrexate use in Felty's syndrome: Correlation of clinical response with neutrophil reactive IgG. Arthritis Rheum 1987; 30:28.
113. WASSENBERG S, HERBORN G, RAU R: Methotrexate treatment in Felty's syndrome. Br J Rheumatol 1988; 37: 908-11.
114. BACHER DE, WILKE WS: Methotrexate in extraarticular rheumatoid disease. In WILKE WS (Ed.): Methotrexate Therapy in Rheumatic Disease. NY, Marcel Dekker 1989.
115. ESPINOZA LR, ESPINOZA CG, VASEY FB, GERMAIN BF: Oral methotrexate therapy for chronic rheumatoid arthritis ulcerations. J Am Acad Dermatol 1986; 15: 508-12.
116. MARKS CR, WILLKENS RF, WILSKEK R, BROWN PB: Small vessel vasculitis and methotrexate. Ann Intern Med 1984; 100: 916.
117. KERSTENS PJSM, BOERBOOMS AMT, JEURISSEN MEC et al.: Accelerated nodulosis during low dose methotrexate therapy for rheumatoid arthritis. An analysis of ten cases. J Rheumatol 1992; 19: 867-71.
118. ALARCON GS, KOOPMAN WJ, McCARTY MJ: Non-peripheral accelerated nodulosis in a methotrexate-treated rheumatoid arthritis patient. Arthritis Rheum 1993; 36:132-3.
119. WEINBLATT ME, KAPLAN H, GERMAIN BF: Methotrexate in rheumatoid arthritis: Effects on disease activity in a multi-center prospective study. J Rheumatol 1991; 18:334-8.
120. GUTIERREZ-URENA S, MOLINA JF, GARCIA CO et al.: Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 1996; 39: 272-6.
121. FEHLAUER CS, CARSON CW, CANNON GW: Methotrexate therapy in rheumatoid arthritis: 2-year retrospective follow up study. J Rheumatol 1989; 16: 307-12.
122. WEINBLATT ME, FRASER P: Elevated mean corpusular volume as a predictor of hematologic toxicity due to methotrexate therapy. Arthritis Rheum 1989; 32: 1592-6.
123. HALLA JT, HARDIN JG: Under-recognized post-dosing reactions to methotrexate in patients with rheumatoid arthritis. J Rheumatol 1994; 21: 1224-6.
124. BERTINO J: The mechanism of action of the folate antagonists in man. Cancer Res 1963; 23: 1286-306.
125. KARGER T, RAU R: Methotrexate therapy of highly active polyarthritis. In RAU R (Ed.): Low Dose Methotrexate Therapy in Rheumatic Diseases. Basel, Karger 1986.
126. KREMER JM, LEE JK: A long-term prospective study of the use of methotrexate in rheumatoid arthritis: update after a mean of fifty-three months. Arthritis Rheum 1988; 31: 477-584.
127. WILLKENS RF, WATSON MA: Methotrexate: A perspective of its use in the treatment of rheumatic disease. J Lab Clin Med 1982; 100: 314-21.
128. GROFF GD, SHENBERGER KN, WILKE WS, TAYLOR TH: Low dose oral methotrexate in rheumatoid arthritis: an uncontrolled trial and review of the literature. Semin Arthritis Rheum 1983; 12: 333-47.
129. MACKINNON SK, STARKEBAUM G, WILLKENS RF: Pancytopenia associated with low-dose pulse methotrexate in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1985; 15: 119-26.
130. CALVO-ROMERO JM: Severe pancytopenia associated with low-dose methotrexate therapy for rheumatoid arthritis. Ann Pharmacother 2001; 35: 1575-7.
131. BUCKLEY LM, VACEK PM, COOPER SM: Administration of folinic acid after low-dose methotrexate in patients with rheumatoid arthritis. J Rheumatol 1990; 17: 1158-61.
132. TANAKA Y, SHIOZAWA K, NISHIBAYASHI Y, IMURA S: Methotrexate-induced early onset pancytopenia in rheumatoid arthritis: Drug allergy? Idiosyncrasy ? J Rheumatol 1992;19: 1320-1.
133. WERNICK R, SMITH DL: Central nervous system toxicity associated with weekly low-dose methotrexate therapy. Arthritis Rheum 1989; 32: 770-5.
134. CANNON GW: Methotrexate pulmonary toxicity. Rheum Dis Clin North Am 1997;23: 917-37.
135. KREMER JM, ALARCON GS, WEINBLATT ME et al.: Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997; 40: 1829-37.
136. WILLIAMS HJ, CANNON GW, WARD JR: Methotrexate induced pulmonary toxicity in patients with rheumatoid arthritis. In RAU R (Ed.): Low Dose Methotrexate Therapy in Rheumatic Diseases. Basel, Karger 1986.
137. DAWSON T, RYAN PFJ, FINDEISEN JM, SCHEINKESTEL CD: Pneumocystis carinii pneumonia following cyclosporine A and methotrexate treated rheumatoid arthritis. J Rheumatol 1992; 19: 997.
138. LANG B, RIEGEL W, PETERS T, PETER HH: Low dose methotrexate therapy for rheumatoid arthritis complicated by pancytopenia and Pneumocystis carinii pneumonia. J Rheumatol 1991; 18: 1257-9.
139. HILLIQUIN P, RENOUX M, PERROT S et al.: Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis. Br J Rheumatol 1996; 35: 441-5.
140. GOLDEN MR, KATZ RS, BALK RA, GOLDEN HE: The relationship of pre-existing lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J Rheumatol 1995; 22: 1043-7.
141. OHOSONE Y, OKANO Y, KAMEDA H et al.: Clinical characteristics of patients with rheumatoid arthritis and methotrexate-induced pneumonitis. J Rheumatol 1997; 24: 2299-303.
142. SALAFFI F, MANGENELLI P, CAROTTI M et al.: Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature. Clin Rheumatol 1997; 16: 296-304.
143. CARSON CW, CANNON GW, EGGER MJ et al.: Pulmonary disease during the treatment of rheumatoid arthritis with low-dose pulse methotrexate. Semin Arthritis Rheum 1987;16: 186-95.
144. WILKE WS, CALABRESE LH, KRALL PL, SEGAL AM: Incidence of toxicity in patients with rheumatoid arthritis treated with methotrexate. In RAU R (Ed.): Low Dose Methotrexate Therapy in Rheumatic Disease. Basel, Karger 1986.
145. DAWSON JK, GRAHAM DR, DESMOND J, FEWINS HE, LYNCH MP: Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatolgy 2002; 41: 262-7.
146. YAZICI Y, ERKAN D, PAGET SA: Monitoring methotrexate hepatic toxicity in rheumatoid arthritis: Is it time to update the guidelines? J Rheumatol 2002; 29: 1586-9.
147. WEINBLATT ME: Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol 1985; (Suppl. 12) 12: 35-39.
148. VAN EDE AE, LAAN RF, ROOD MMJ et al.: Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multi-center, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001; 44: 1515-24.
149. RAU R: Toxicity of methotrexate in rheumatoid arthritis. In WEINBLATT ME (Ed.): A Comprehensive Guide to New Therapeutic Approaches of Methotrexate in Rheumatoid Arthritis. Chicago, Pharma Libri 1987; 63-77.
150. PHILLIPS C, CERA PJ, MANGAN TF, NEWMAN ED: Clinical liver disease in rheumatoid arthritis patients on methotrexate. J Rheumatol 1992; 19: 229-33.
151. KREMER JM, LEE RG, TOLMAN KG: Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples. Arthritis Rheum 1989;32: 121-7.
152. BJORKMAN DJ, HAMMOND EH, LEE RG et al.: Hepatic ultrastructure after methotrexate therapy for rheumatoid arthritis. Arthritis Rheum 1988; 31: 1465-72.
153. KREMER JM: Liver biopsies in patients with rheumatoid arthritis receiving methotrexate: Where are we going? J Rheumatol 1992; 19:189-91.
154. KREMER JM, FURST DE, WEINBLATT ME, BLOTNER SD: Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis. J Rheumatol 1996; 23: 459-61.
155. ROENIGK HH, MAIBACH HI, WEINSTEIN G: Guidelines on methotrexate therapy for psoriasis. Arch Dermatol 1972; 105: 363-5.
156. BEYELER C, REICHEN J, THOMANN SR et al.: Quantitative liver function in patients with rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study. Br J Rheumatol 1997; 36: 338-44.
157. LEFKOWITZ AM, FARROW IJ: The liver in rheumatoid disease. Ann Rheum Dis 1955;14: 162-8.
158. RAU R: Die Leber bei entzündlich-rheumatischen Erkrankungen (The liver in inflammatory rheumatic diseases). Steinkopff, Darmstadt 1978.
159. RAU R, KARGER T, HERBORN G, FRENZEL H: Liver biopsy findings in patients with rheumatoid arthritis undergoing long-term treatment with methotrexate. J Rheumatol 1989; 16: 489-93.
160. RAU R, FRENZEL H, CEPIN A, HERBORN G: 131 liver biopsies of MTX-treated RA patients compared with 135 pre-treatment biopsies. Arthritis Rheum 1992; 35: S147 (abstract).
161. MACKENZIE AH: Liver biopsy findings after prolonged methotrexate therapy for rheumatoid arthritis. In RAU R (Ed.): Low Dose Methotrexate Therapy in Rheumatic Diseases. Basel, Karger 1986.
162. APONTE J, PETRELLI M: Histopathologic findings in the liver of rheumatoid arthritis patients treated with long-term bolus methotrexate. Arthritis Rheum 1988; 31: 1457-64.
163. KREMER JM, LEE RG, TOLMAN KG: Liver histology in rheumatoid arthritis patients receiving longterm methotrexate therapy. Arthritis Rheum 1989; 32: 121-7.
164. KREMER JM, KAYE GI, KAYE NW et al.: Light and electron microscopic analysis of sequential liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy. Follow-up over long-term treatment intervals and correlation with clinical and laboratory variables. Arthritis Rheum 1995; 38: 1194-203.
165. KREMER JM, KAYE GI: Electron-microscopic analysis of sequential liver biopsy samples from patients with rheumatoid arthritis: Correlation with light microscopic findings. Arthritis Rheum 1989; 32: 1202-13.
166. WALKER AM, FUNCH D, DREYER NA et al.: Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum 1993; 36: 329-35.
167. SINGH G, FRIES JF, WILLIAMS CA et al.: Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 1994; 18: 188-94.
168. VAN DER VEEN MJ, VAN DER HEIJDE A, KRUIZE AA, BIJLSMA JW: Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 1994; 53: 224-8.
169. BOERBOOMS AM, KERSTENS PJ, VAN LOENHOUT JW et al.: Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum 1995; 24:411-21.
170. KERSTENS PJ, VAN LOENHOUT JW, BOERBOOMS AM, VAN DE PUTTE LB: Methotrexate, pneumonitis, and infection. Ann Rheum Dis 1992; 51: 1179.
171. ALTZ-SMITH M, KENDALL LG, STAMM AM: Cryptococcosis associated with low-dose methotrexate for arthritis. Am J Med 1987; 83: 179-81.
172. ANTONELLI MAS, MORELAND LW, BRUCK JL: Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. Am J Med 1991; 90: 295-8.
173. OSTUNI P, BOTSIOS C, PUNZI L, SFRISO P, TODESCO S: Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003; 62: 686-7.
174. BINYMIN K, COOPER RG: Late re-activation of spinal tuberculosis by low-dose methotrexate therapy in a patient with rheumatoid arthritis. Rheumatology 2001; 40: 341-2.
175. DI GIROLAMO C, PAPPONE N, MELILO E: Cavitary lung tuberculosis in a rheumatoid arthritis patient treated with low-dose methotrexate and steroid pulse therapy. Br J Rheumatol 1997; 37: 1136-8.
176. GRENNAN DM, GRAY J, LOUDON J, FEAR S: Methotrexate and early post-operative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 2001; 60: 214-7.
177. SEIDEMAN P, MÜLLER-SUUR R, EKMAN E: Renal effects of low dose methotrexate in rheumatoid arthritis. J Rheumatol 1993; 20: 1126-8.
178. KREMER JM, PETRILLO GF, HAMILTON RA: Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. J Rheumatol 1995; 22: 38-40.
179. SEGAL AM, WILKE S: Toxicity of low-dose methotrexate in rheumatoid arthritis. In WILKE WS (Ed.): Methotrexate Therapy and Rheumatic Diseases. NY, Basel, Marcel Dekker 1989.
180. SEGAL AM, KOZLOWSKI RD, STEINBRUNNER JV et al.: Outcome to first trimester exposure to low-dose methotrexate (MTX) in eight pregnant rheumatoid arthritis (RA) patients. Arthritis Rheum 1987; 30: 59.
181. BUCKLEY LM, BULLABOY CA, LEICHTMAN L, MARQUEZ M: Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheum 1997; 40: 971-3.
182. NYFORS A: Methotrexate hepatotoxicity in psoriasis and psoriatic arthritis. A review. In RAU R (Ed.): Low Dose Methotrexate Therapy in Rheumatic Diseases. Basel, Karger 1986.
183. PADEH S, SHARON N, SCHIBY G et al.: Hodgkin's lymphoma in systemic onset juvenile rheumatoid arthritis after treatment with low dose methotrexate. J Rheumatol 1997; 24: 2035-7.
184. JARDINE DL, COLLS BM: Hodgkin's disease following methotrexate therapy for rheumatoid arthritis. NZ Med J 2002; 115: 293-4.
185. DUBIN-KERR L, TROY K, ISOLA L: Temporal association between the use of methotrexate and development of leukemia in 2 patients with rheumatoid arthritis. J Rheumatol 1995; 22: 2356-8.
186. GEORGESCU L, QUINN GC, SCHWARTZMAN S, PAGET SA: Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum 1997; 26: 794-804.
187. DAWSON TM, STARKEBAUM G, WOOD BL et al.: Epstein-Barr virus, methotrexate, and lymphoma in patients with rheumatoid arthritis and primary Sjögren's syndrome: Case series. J Rheumatol 2001; 28: 47-53.
188. STARKEBAUM G: Rheumatoid arthritis, methotrexate, and lymphoma: risk substitution, or cat and mouse with Epstein-barr virus ? J Rheumatol 2001; 28: 2573-5.
189. SCHNABEL A, BURCHARDI C, GROSS WL: Major infection during methotrexate treatment for rheumatoid arthritis. Semin Arthritis Rheum 1996; 25: 357-9.
190. SALLOUM E, COOPER DL, HOWE G et al.: Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 1996; 14: 1943-9.
191. MODER KG, TEFFERI A, COHEN MD et al.: Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study. Am J Med 1995; 99: 276-81.
192. BAIRD RD, VAN ZYL-SMIT RN, DILKE T, SCOTT SE, RASSAM SMB: Spontaneous remission of low-grade B-cell non-Hodgkin's lymphoma following withdrawal of methotrexate in a patient with rheumatoid arthritis: case report and review of the literature. Br J Haematol 2002; 118: 567-8.
193. STEWART M, MALKOVSKA V, KRISHNAN J, LESSIN L, BARTH W: Lymphoma in a patient with rheumatoid arthritis receiving methotrexate treatment: successful treatment with rituximab. Ann Rheum Dis 2001; 60: 892-3.
194. VERSTRAETEN A, DEQUEKER J: Vertebral and peripheral bone mineral content and fracture incidence in post-menopausal patients with rheumatoid arthritis: Effects of low-dose corticosteroids. Ann Rheum Dis 1986; 45: 852-7.
195. FRIEDLANDER GE, TROSS RB, DOPGANIS AC et al.: Effects of chemotherapeutic agents on bone. J Bone Joint Surg 1984; 66: 602-7.
196. MAY KP, WEST SG, McDERMOTT MT, HUFFER WE: The effect of low dose methotrexate on bone metabolism and histomorphometry in rats. Arthritis Rheum 1994; 37: 201-6.
197. BUCKLEY LM, LEIB ES, CARTULARO KS et al.: Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 1997; 24: 1489-94.
198. CRANNEY AB, McKENDRY RJ et al.: The effect of low dose methotrexate on bone density. J Rheumatol 2001; 28: 2395-9.
199. CRONSTEIN BN: Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum 1996; 39: 1951-60.
200. MORGAN SL, DAGGOTT JE, VAUGH WH et al.: The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990; 33: 9-18.
201. WEINBLATT ME, MAIER AL, COBLYN JS: Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8-week randomised placebo-controlled trial. Arthritis Rheum 1993; 20: 950-2.
202. SHIROKY JB, NEVILLE C, ESDAILE JM et al.: Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Arthritis Rheum 1993; 36: 795-803.
203. BUCKLEY LM, VACEK PM, COOPER SM: Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol 1990; 17: 1158-61.
204. TISHLER M, CASPI D, FISHEL B, YARON M: The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients. Arthritis Rheum 1988; 31: 906-8.
205. HANRAHAN PS, RUSSELL AS: Concurrent use of folinic acid and methotrexate in rheumatoid arthritis. J Rheumatol 1988; 15: 1078-80.
206. JOYCE DA, WILL RK, HOFFMANN DM et al.: Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann Rheum Dis 1991; 59: 913-4.
207. ANDERSEN LS, HANSEN EL, KNUDSEN JB et al.: Prospectively measured red cell folate levels in methotrexate treated patients with rheumatoid arthritis: relation to withdrawal and side effects. J Rheumatol 1997; 24: 830-7.
208. MORGAN SL, BAGGOT JE, ALTZ-SMITH M: Folate status of rheumatoid arthritis patients receiving long-term, low-dose methotrexate therapy. Arthritis Rheum 1987; 30: 1348-56.
209. WHITTLE SL, HUDGES RA: Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology 2004; 43: 267-71.
210. MORGAN SL, BAGGOTT JE, LEE JY et al.: Folic acid supplementation prevents deficient blood folate levels and hyperhomocyteinemia during long-term, low-dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol 1998; 25: 441-6.
211. VAN EDE AE, LAAN RF, BLOM HJ et al.: Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology 2002; 41: 658-65.
212. CHOI HK, HERNAN MA, SEEGER JJD, ROBINS JM, WOLFE F: Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-7.
213. VAN DOORNUM S, McCOLL G, WICKS IP: Accelerated atherosclerosis: an extra-articular feature of rheumatoid arthritis ? Arthritis Rheum 2002; 46: 862-73.
214. KRAUSE D, SCHLEUSSER B, HERBORN G, RAU R: Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000; 43: 14-21.
215. LANDEWE RBM, VAN DEN BORNE BEEM, BREEDVELD FC, DIJKMANS BAC: Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. Lancet 2000; 355: 1616-17.
216. JENSEN OK, RASMUSSEN C, MOLLERUP F et al.: Hyperhomocysteinemia in rheumatoid arthritis: influence of methotrexate treatment and folic acid supplementation. J Rheumatol 2002; 29: 1615-8.
217. KREMER JM, ALARCON GS, LIGHTFOOD RW Jr et al.: Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37: 316-28.